



Martin Dreyling

Kontakt

Martin Dreyling

Publikationen (2)

Novak U, Fehr M, Schär S, Dreyling M, Schmidt C, Derenzini E, Zander T, Hess G, Mey U, Ferrero S, Mach N, Boccomini C, Böttcher S, Voegeli M, Cairoli A, Ivanova V, Menter T, Dirnhofer S, Scheibe B, Gadiant S, Eckhardt K, Zucca E, Driessen C, Renner C. Combined therapy with ibrutinib and bortezomib followed by ibrutinib maintenance in relapsed or refractory mantle cell lymphoma and high-risk features: a phase 1/2 trial of the European MCL network (SAKK 36/13). *EClinicalMedicine* 2023; 64:102221.

Klapper W, Möller P, Barth T, Muller-Hermelink K, Rosenwald A, Ott G, Pileri S, Ralfkiaer E, Rymkiewicz G, van Krieken J, Wacker H, Unterhalt M, Hiddemann W, Dreyling M, Stein H, Loddenkemper C, Hoster E, Determann O, Oschlies I, van der Laak J, Berger F, Bernd H, Cabeçadas J, Campo E, Cogliatti S, Hansmann M, Klün P, Kodet R, Krivolapov Y, for the European MCL Network. Ki-67 as a prognostic marker in mantle cell lymphoma-consensus guidelines of the pathology panel of the European MCL Network. *Journal of hematopathology* 2009

Projekte (0)

Keine Resultate gefunden.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch